Why Attend
Protein degradation has redefined the drug discovery landscape, offering a promising solution in the quest to ‘drug the undruggable’. Whilst over the past few years this field as witnessed unprecedented growth, investment, and intrigue (around €4 billion worth, to be precise), 2021 is set to be another showstopper for targeted protein degradation with 15 compounds predicted to enter the clinic by the end of the year.
As we enter a new wave of drug discovery:
- Explore the clinical viability of protein degraders including discussions on delivery methods, optimisation strategies and DMPK & SAR parameters
- Learn how multispecifics that form connections between POIs and cellular machinery are expanding drug amenability of proteins in this untapped, new wave of medicine.
- Reach “undruggable” high-hanging fruit using chemoproteomics platforms including DNA encoded libraries and covalent ligand discovery
Poster Submission 2021
Looking to showcase your recent work to the protein degradation community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Poster abstract submission deadline is on 17 August 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Previous Attendees Include
Audience Breakdown
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
2021 Partners
Gold Partner
Promega
Website: https://www.promega.com
Promega is committed to excellence in technologies and compound profiling services to assess key processes in Targeted Protein Degradation and Induced Proximity mechanisms. From assessing protein degradation in real time, to understanding compound binding and permeability, to ternary complex formation and more. Our CRIPSR HiBiT content covers hundreds of pre-built targets. Novel software analysis tools allow for the determination of target protein degradation rates, DC50 potency values, recovery profiles and more.
Expertise Partner
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need.
Event Partners
Fluidic Analytics
Website: https://www.fluidic.com/
Fluidic Analytics- Understand the machinery of life
With the right tool, protein researchers can change the world around us.
Our award-winning technologies open doors for scientists to understand proteins and their behavior better than ever before. By characterizing proteins and their interactions, scientists can make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. Our revolutionary technologies give researchers a fundamentally new way to analyze proteins without compromise, because we truly believe the right tools in the right hands will change the world.
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
Excelra
Website: https://www.excelra.com/
Excelra’s Degrader Databases and Services help augment the Targeted Protein Degradation efforts. The dynamic & evolving TPD space comes with various challenges such as the limited number of E3 ligases, selecting an amenable target, and optimizing compounds.
Our Degraders Intelligence Database and Degrader Discovery Database offerings address these challenges and accelerate the efficiency of the companies working in targeted protein degradation areas.
With our domain expertise and extensive experience in data wrangling, Excelra has been a preferred partner for Life sciences for over 18 years. Excelra's data and analytics solutions empower innovation in life sciences across the value chain from discovery to market.
Liverpool ChiroChem
Website: https://www.liverpoolchirochem.com/
Liverpool ChiroChem (LCC) is a chemical technology innovator that produces chiral small molecules for biotech/pharmaceutical R&D. As the Home of Chiral N-Heterocycles, our initial focus is the production and supply of sp3-rich chiral N- heterocycles, readily accessible, chirally pure and available on scale. The harnessed expert synthetic technologies provide efficient access to a variety of novel, compact, chiral building blocks, in order to facilitate access to new chemical space for hit identification and potential further hit expansion. Finally, our proprietary products are ideally suited for DNA-Encoded Library synthesis and Fragment Based Lead Discovery, which many medicinal chemists consider to be the two leading areas of modern-day drug discovery.
Dynamic Biosensors
Website: https://www.dynamic-biosensors.com/
Dynamic Biosensors is a young biotech company based in Munich, Germany, and in Boston (MA), USA. We provide innovative measurement technologies for the analysis of molecular interactions, which enable life science researchers in academia and industry to achieve scientific breakthroughs and develop future medicines against cancer and many other diseases.
Dynamic Biosensors commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development.
Selvita
Website: https://selvita.com/
Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development.
The company was established in 2007 and as a Selvita Group of companies currently employs over 750 professionals. At the beginning of 2021, Selvita completed its acquisition of Fidelta – Croatian CRO company. This corporate milestone provides a significant increase in business scale and solid foundations for further growth.
We are headquartered in Krakow, Poland, with a second research site in Poznan, Poland, while Fidelta is located in Zagreb, Croatia. Our foreign offices are located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK. Specialising in delivering integrated solutions Selvita has a proven track record of not just providing scientific excellence, but on building long-term partnerships with our clients and playing an active, consultative role in the project execution.
FENIX - CELLTELIGENCE
Website: https://celltelligence.com/
Please visit our website for more information.BioTheryX
Website: https://www.biotheryx.com/
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven clinical and commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule is currently in Phase I clinical trial for Acute Myeloid Leukemia and high-risk MDS and our lead protein degradation “molecular glue” molecule (Protein Homeostatic Modulator or PHM®) will be in the clinic in 2021 for hematological malignancies.
What attendees say
2021 Speakers
Benedict Cross
Carlotta Cecchini
Carlotta Cecchini received her Master’s degree in 2017 in Pharmaceutical Sciences at the University of Bologna Bologna (Italy), where she was awarded a scholarship for two consecutive years (2015/2016) for her excellent grades. In 2018, she joined the group of Prof. Leonardo Scapozza (Biochemistry/Chemistry group) at the University of Geneva to start a Ph.D. in medicinal chemistry. Her research topic mainly focuses on the design and synthesis PROTACs as oncogenic agents. Through her thesis work, Carlotta gained experience in the field of Targeted Protein Degradation, and in particular, in PROTAC rational design. She plans to obtain her Ph.D. degree by the end of 2022.
Christina Woo
Constantine Mitsiades
Daniel Nomura
Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies.
Christopher Hickey
Anthony Slavin
Arthur T. Sands, M.D., Ph.D.
Elmar Wolf
Owen Wallace
Fu-Sen Liang
Scott Hughes
Diogo Feleciano
Gaoqi Weng
Kristin Riching
Kristin received her Ph.D. in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibre networks and their effects on breast cancer cell migration in invasive ductal carcinoma. She joined Promega in 2014 as a postdoctoral researcher to study the pharmacology of ligand-dependent responses within the ErbB signalling network. Currently, she is a Senior Scientist developing technologies and approaches for live cell characterization of protein degradation and protein interactions within the ubiquitin proteasome pathway.
Laura Itzhaki
Leah Fung
Matthias Brand
Riccardo De Matos Simoes
Sandra Kumper
Sumona Mitra
Sara Pannilunghi
Sara Pannilunghi received her degree in Pharmacy with a Master in Pharmaceutical Chemistry and Technology from the University of Bologna (Italy) in 2018. After a brief experience with the solid-state synthesis of anti-VEGF peptides (Paris Descartes University), she contributed during her Master’s thesis to developing novel α-Carboline inhibitors of the Anaplastic Lymphoma Kinase (University of Geneva). In late 2018, Sara started a Ph.D. in Medicinal Chemistry and Biochemistry in Prof. L. Scapozza’s group at the University of Geneva. Her current project focuses on the conception, synthesis, and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) employed against drivers of chronic inflammation.
Dr. Debasis Pore
Stina Lundgren
Thomas Hayhow
Tom Shepherd
Dr. Tom Shepherd is Chief Executive Officer of Captor Therapeutics, a drug discovery company focused on Targeted Protein Degradation listed on the Warsaw Stock Exchange since its IPO in 2021, with laboratory facilities in Poland and in Switzerland.
Tom has a Ph.D. in Biochemistry from the University of Strathclyde in his native Scotland. Following an early career in the Medical Department of Novartis, he has since primarily worked in Business Development and General Management roles internationally in drug discovery companies in the UK, California, France, Australia, and Switzerland, including with Bausch-Health and Kymab, prior to joining Captor Therapeutics in Poland in 2019.
Yifat Merbl
Yu Rao
Zuzanna Kozicka
I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.
The Agenda
Please complete the from to receive the full agenda for 2021, including information about the key topics being covered, speakers, and why you should attend.
What you can expect from the 2021 congress:
- 200+ participants from leading industry players within big pharma and biotech along with expert academics and service providers.
- An open forum to share the latest in vivo and in vitro data and insights and foster collaboration.
- 20+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
- 3 days of progressing translation of protein degradation probes into safe, effective therapeutics.
Download Agenda
highlights from previous years
The Virtual Experience
Top 10 benefits
- Tailor Your Agenda
- More Audience Participation
- Improved Audience Visibility
- On-Demand Content
- High Quality Speakers
- More Networking Opportunities
- Save Time & Money
- Increased Content
- More insights
- Business Development Opportunities - Talk to our team to find out out more [email protected].
Platform Preview
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.